Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including Forms 10-K, 10-Q and 8-K. As a biotechnology company developing and commercializing therapies for gastrointestinal (GI) and rare diseases, Ironwood uses these filings to report on its financial condition, collaboration revenues from LINZESS® (linaclotide), progress of its apraglutide program, capital structure and risk factors.
In its annual reports on Form 10-K, Ironwood presents audited financial statements, management’s discussion and analysis of results, details on its GI and rare disease portfolio, and information about collaborations with partners such as AbbVie, Astellas and AstraZeneca. These filings also describe material weaknesses in internal control over financial reporting identified as of December 31, 2024, and the company’s efforts to address them.
Quarterly reports on Form 10-Q update investors on interim financial performance, including collaboration revenue tied to LINZESS U.S. net sales, research and development expenses related to apraglutide and other programs, restructuring charges, interest expense on convertible senior notes and revolving credit facilities, and non-GAAP measures such as adjusted EBITDA and non-GAAP net income or loss.
Current reports on Form 8-K provide timely disclosure of specific events. For Ironwood, 8-K filings in 2025 have covered topics such as Nasdaq notifications about bid price and filing timeliness, the company’s receipt of a Maximum Fair Price determination for LINZESS under the Inflation Reduction Act, changes in the independent registered public accounting firm, director resignations, and the public release of quarterly earnings press releases.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries designed to highlight key points from lengthy documents, such as shifts in financial guidance, updates on the apraglutide regulatory path, or changes in collaboration economics. Users can quickly identify information related to annual reports (10-K), quarterly reports (10-Q) and current reports (8-K), and can review disclosures that affect listing status, internal controls, and major GI and rare disease programs.
This page also helps investors monitor governance and compliance developments, including responses to Nasdaq listing rules and auditor changes, alongside the financial and operational data that shape the IRWD investment profile.